Anti-Obesity Drugs Market Analysis

Anti-Obesity Drugs Market Analysis

Based on product, the market is bifurcated into prescription drugs and OTC drugs. The global market was estimated at USD 5.6 billion in 2023. The prescription drugs segment held revenue of USD 4.1 billion in 2023 and the segment is poised for significant growth at a CAGR of 27.1% during the forecast period.
 

• Prescription drugs play a vital role in the market by offering effective weight management options under medical guidance. These medications focus on the treatment of obesity mechanism such as hunger, fat absorption, metabolic rates, making them more effective treatment options than OTC drugs.
   
• Additionally, these drugs are formed to address specific individual needs, often based on healthcare providers evaluation of particular individuals’ health conditions such as BMI, comorbidities, and other risk factors. For instance, according to the estimates, obesity affects approximately 42% of adults in U.S., creating the demand for clinically proven medication to treat obesity.
   
• In parallel, clinical studies have also shown significant improvement in weight loss up to 15% to 20% in patient by using Semaglutide and Trizepatide drugs.
   
• Furthermore, prescription medication formulations require various clinical testing and regulatory approvals, ensuring their safety and efficacy. With the support of  health providers to monitor the progress and the side effects associated with the drugs, thus these medications offer reliable option for long term obesity management and accelerating the growth of the market.

Based on action pathway, the anti-obesity drugs market is bifurcated into peripherally acting drugs and centrally acting drugs. The centrally acting drugs segment accounted for a revenue share of 63.6% and with revenue of USD 3.5 billion in 2023.
 

• The central acting drugs have substantial potential in the anti-obesity market, by targeting the brain’s appetite control centers to regulate hunger and satiety.
   
• These medications act at the level of neurotransmitters which includes dopamine, norepinephrine, and serotonin to minimize food cravings and increase feeling of food fluffiness, which help individuals to maintain their weight and calorie intake more effectively.
   
• For instance, according to data from clinical trials, medicines such as Phentermine-Topiramate and Naltrexone-Bupropion have shown positive result in undergoing weight loss of individuals, up to 5% to 10% of their total body weight.
   
• Additionally, the rising incidence of obesity and its related health complications has increased the need for effective treatments, promoting research and development efforts to specifically focused on centrally acting medications.
   

Based on distribution channel, the anti-obesity drugs market is segmented into retail pharmacies, e-commerce, drug stores, and hospital pharmacies. The retail pharmacies segment held the largest revenue of USD 2.3 billion in 2023.
 

• The dominance of this segment is largely attributed due to its widespread accessibility, retail pharmacies are broadly available, making it an easier way for patients to obtain medicine without a need of doctor’s prescription. This is specifically benefited for those patients living in remote or underserved areas.
   
• Retail pharmacies also educate patients about the anti-obesity medications, their side effects and proper usage. They also provide personalized counselling, helping patients to know the difference between the OTC drugs and prescription drugs for weight loss.
   
• Furthermore, these pharmacies also offer services such as extended operating hours and nearby locations, which improves patient adherence to treatment regimens, leading to better patient outcomes and also contributing to the market growth.

The North America anti-obesity drugs market is accounted for 2.5 billion revenues in 2023 forecasted to reach USD 21.9 billion by 2032. The U.S. dominated the North America market with the largest revenue of USD 2.3 billion in 2023.
 

• The rising incidence of chronic disorders such as type 2 diabetes, cardiovascular diseases, and obesity are on rise in the U.S., is accelerating the demand for the anti-obesity drugs.
   
• For instance, in 2021, as per the data from the Centers for Disease Control and Prevention (CDC), reports that approximately 38.4 million individuals in U.S. suffered from diabetes, about which 90% to 95 % individuals suffered from type 2 diabetes, resulting for about 11.6% of the total global population.
   
• Moreover, the rise in obesity is also influenced by cultural and lifestyle factors which includes the availability of high calorie food, sedentary habits, further contributing to the obesity cases, which underscores the need for effective treatment option such as weight loss medication.
   

Europe: Anticipate significant growth in UK’s anti-obesity drugs market from 2024 to 2032.
 

• The growth of anti-obesity market in this region is anticipated to be bolstered by the UK governments commitment towards tacking obesity via initiatives such as public health campaigns, regulatory measures aiming towards unhealthy food marketing, and guidelines that promoting the healthier lifestyle, is contributing to the market growth.
   
• For instance, according to the health survey conducted by government of England estimates that in 2021, 25.9% of individuals were obese and 37.9% were overweight, of total population.
   
• To tackle this issue, the government of UK has launched a Euro 40 million pilot program to increase the accessibility of weight loss treatment for patients, outside the hospital.
   

Asia pacific: Japan anti-obesity drugs market is poised for substantial growth between 2024 and 2032.
 

• The rising incidence of obesity and obesity-related health disorder such as type 2 diabetes and cardiovascular disease,  thereby accelerating the market growth. 
   
• For instance, according to the report from Internation Diabetes Federation (IDF), estimates that in 2021, 11,004,999 individuals were diabetic, which is 11.8% of total the population.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policymakers for the need of effective strategies to come over the obesity and its related health conditions.
   
• Further, Japan also has leading pharmaceutical companies which has great capabilities in drug development such as anti-obesity medications.
   

Middle East and Africa: Expect noteworthy growth in Saudi Arabia's anti-obesity drugs market from 2024 to 2032.
 

• Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced anti-obesity medicine tailored to the country’s patient specific needs.
   
• Further, the growing case of obesity is creating the heightened demand for  anti-obesity drugs in Saudi Arabia.
   

For instance, according to the data from National Institute of Health (NIH), in 2023, one fifth of the population was overweight or obese, which is 9.4%. The rising obesity cases was highest among children aged between 2 to 6 years is 12.3%, which was highest among boys, 10.4% than girls, 8.3%.